Search Results

Latisse appeal scottish web intellectual property.

• Authors : Rosen, Ellen (AUTHOR)

Subjects: *INTELLECTUAL property; *BUSINESS planning; *BUSINESS finance

• Source: Bloomberg.com. 9/15/2014, pN.PAG-N.PAG. 1p.

Record details

FASTER ROUTE TO PROSTAGLANDINS.

• Authors : Halford, Bethany

Subjects: *DRUG prices; PROSTAGLANDIN synthesis; BIMATOPROST

• Source: Chemical & Engineering News. 8/20/2012, Vol. 90 Issue 34, p9-9. 1p.

Record details

C2 PHARMA expands ophthalmic API portfolio with tropicamide launch & multiple regulatory filings.

Subjects: TROPICAMIDE; BIMATOPROST; ANTIHYPERTENSIVE agentsUNITED States. Food & Drug Administration

• Source: FRPT - Global Chemical Snapshot. 11/10/2022, p28-29. 2p.

Record details

A Welcome Change: The Benefits of Reformulation: Reformulation strategies can provide drug developers with a head start to achieve promising options that benefit the patient.

• Authors : Thomas, Felicity

Subjects: SOLID dosage forms; DRUG side effects; GENERIC drugs

• Source: Pharmaceutical Technology. May2020, Vol. 44 Issue 5, p28-30. 3p.

Record details

Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail.

• Authors : Waldron, James (AUTHOR)

Subjects: EYE diseases; LIFE sciences; GLAUCOMA

• Source: FierceBiotech. 6/10/2024, pN.PAG-N.PAG. 1p.

Record details

A Welcome Change: The Benefits of Reformulation: Reformulation strategies can provide drug developers with a head start to achieve promising options that benefit the patient.

• Authors : Thomas, Felicity

Subjects: *MEDICAL personnel; SOLID dosage forms; DRUG side effects

• Source: Pharmaceutical Technology Europe. May2020, Vol. 33 Issue 5, p16-18. 3p.

Record details

Bimatoprost and similar eye drops: enophthalmos.

• Source: Prescrire International. Dec2020, Vol. 29 Issue 221, p299-300. 2p.

Record details

Alcon to Acquire Aerie Pharmaceuticals for US$770 M.

• Authors : Haggerty, Lucy¹

Subjects: *MERGER agreements; OPHTHALMIC drugs; DRY eye syndromesNOVARTIS AG 001221845 NOVARTIS AG NOVARTIS AG 001221845 001221845 NOVARTIS AG 001221845 NVS

• Source: PharmaDeals Review. Aug2022, Vol. 2022 Issue 8, p7-7. 1p.

Record details

Alembic receives USFDA tentative approval for bimatoprost ophthalmic solution.

Subjects: DRUG approvalALEMBIC Pharmaceuticals Ltd.

• Source: FRPT- Chemical Snapshot. 8/27/2019, p16-17. 2p.

Record details

Alembic receives USFDA nod for Bimatoprost Ophthalmic Solution.

Subjects: DRUGSINDIAALEMBIC Pharmaceuticals Ltd.

• Source: FRPT- Chemical Snapshot. 4/23/2019, p10-11. 2p.

Record details